How Diverse Skills Can Drive Success in Biotech
May 2nd 2024In this Pharmaceutical Executive video interview, Chris Martin, Chief Commercial Officer, Verona Pharma, discusses which skills or experiences he thinks are most valuable for team members tasked with launching a novel treatment in a competitive market.
Shifting Priorities and Perceptions in Revenue Management
May 1st 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, discusses the changing dynamics today for companies in revenue management and planning—and the increasing importance of a well-tooled and well-trusted analytics component in fueling product launch, M&A, and other data-centered pursuits.
Why Early Communication is Crucial for a Successful Drug Launch
May 1st 2024In this Pharmaceutical Executive video interview, Chris Martin, Chief Commercial Officer, Verona Pharma, discusses specific advantages for a small biotech company in crafting a unique commercialization strategy and the importance of starting early and getting aligned.
2023 Patient Access: State Legal and Regulatory Environment Survey Objectives and Strategies
April 22nd 2024In this Pharmaceutical Executive video interview, Jon Hamrick, Partner, Curatio Scientia Advisors and Jon Rawlson, President & Founder, Armory Hill Advocates, discusses how they went about testing their various hypotheses for the 2023 Patient Access: State Legal and Regulatory Environment Survey and how they collected the data.
Novo Nordisk Foundation Executive Talks Biomedical Quantum Sensing
April 17th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Lene Oddershede, SVP, Natural & Technical Sciences, Novo Nordisk Foundation discusses a recent grant awarded to the Copenhagen Center for Biomedical Quantum Sensing.
Opening the Door for More NASH Patients
April 1st 2024In this Pharmaceutical Executive video interview, Optum Rx clinical pharmacist, Arash Sadeghi, discusses developments for non-invasive diagnostics for liver disease and how such advancements could potentially impact the landscape of conditions like NASH.
Addressing Uncertainties Associated Medication Approved Through Accelerated Approval Pathway
March 28th 2024In this Pharmaceutical Executive video interview, Optum Rx clinical pharmacist, Arash Sadeghi, discusses how healthcare providers and patients navigate the potential benefits and uncertainties associated with a medication approved through the accelerated approval pathway.
Petros Pharmaceuticals Executive Discusses Wider Availability of Oral Contraceptive
March 28th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Fady Boctor, President, Chief Commercial Officer, Petros Pharmaceuticals talks about the recent availability of Opill as an over-the-counter (OTC) contraceptive.
Challenges in Trial Access and Treatment for Women with Chronic Illnesses
March 27th 2024In this Pharmaceutical Executive video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, discusses the specific challenges women with chronic illnesses face when it comes to accessing and participating in clinical research.
Do Mixed Results Impact Potential Real-World Effectiveness and Potential Market Adoption?
March 26th 2024In this Pharmaceutical Executive video interview, Optum Rx clinical pharmacist, Arash Sadeghi, explore mixed trial results impact the confidence in their potential real-world effectiveness and potential market adoption.
UCB's Women of Childbearing Age Program
March 25th 2024In this Pharmaceutical Executive video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, talks about the program's creation and their most successful strategies for encouraging the inclusion of women of childbearing age in clinical trials.
Addressing Unmet Needs in Schizophrenia, Pulmonary Arterial Hypertension & NASH
March 22nd 2024In this Pharmaceutical Executive video interview, Optum Rx clinical pharmacist, Arash Sadeghi, discusses the three drugs featured in their Drug Pipeline Insights Report for 2024 and which unmet needs they address.